What is Utah Medical Products Inc worth?
With the base-case assumptions below, a discounted cash flow model on Utah Medical Products Inc's reported free cash flow gives $80.73 per share. The share price was $74.18 on September 25, 2026, 8% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -7.0% | 10.0% | $60.75 | -18% |
| Base | -2.0% | 9.0% | $80.73 | +9% |
| Bull | 3.0% | 8.0% | $118.01 | +59% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $94.34 | $98.39 | $103.34 | $109.53 | $117.49 |
| 8.0% | $84.26 | $86.89 | $90.00 | $93.72 | $98.28 |
| 9.0% | $76.86 | $78.66 | $80.73 | $83.15 | $86.00 |
| 10.0% | $71.19 | $72.46 | $73.91 | $75.57 | $77.48 |
| 11.0% | $66.70 | $67.64 | $68.68 | $69.86 | $71.20 |
Where the presets come from
Base: years 1 to 5 grow at Utah Medical Products Inc's revenue growth rate over the last 5 fiscal years (-1.8% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions